Fig. 4From: SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphomaDLBCL cell apoptosis experiment. The results of cell apoptosis showed that compared with the OCI-LY1 + SLC27A2-siRNA-817 group, the cell apoptosis rate was significantly reduced (A, B). Therefore, low expression of SLC27A2 significantly inhibited the apoptosis of DLBCL cellsBack to article page